Skip to main content
OpenTrials
Completed

NCT Number: NCT00280267

Testosterone Therapy After Hip Fracture in Elderly Women

The purpose of this study is to determine the feasibility of testosterone replacement therapy in frail elderly female hip fracture patients who have testosterone deficiency, and to obtain preliminary information about the effects of testosterone therapy on muscle strength and size, bone density, mobility, daily functioning, and quality of life.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Washington University School of Medicine, Division of Geriatrics and Nutritional Science

St Louis, Missouri, 63110, United States

About this study

Hip fractures are common among elderly women and can have a devastating impact on their ability to remain independent. A significant functional decline following a hip fracture has been documented, and many patients have persistent strength and mobility deficits that impair their capacity for independent function. Such individuals are at high risk for continued supportive services, recurrent injury, and institutionalization. High-risk patients include those with deficits in skeletal muscle strength during the post-fracture period. Age-associated androgen deficiency contributes to deficits in muscle mass and strength that are common in this patient population. The role of testosterone therapy for improving deficits in muscle mass, strength, and functional capacity in the frail elderly is unclear, particularly for elderly women. There is insufficient information regarding tolerability of testosterone therapy, and the appropriate medication dosage and target serum testosterone levels necessary to induces changes in skeletal muscle mass and functional measures in elderly women with physical frailty due to muscle weakness.

The goals of this project are to conduct a randomized, double-blinded, placebo-controlled prospective study to determine the feasibility, tolerability, and safety of 6 months of testosterone therapy in community-dwelling, physically frail, elderly female hip fracture patients. Twenty-seven female hip fracture patients will be recruited, using objective criteria for testosterone deficiency and frailty. We plan to evaluate two dosages of testosterone, administered as a 0.5% topical gel: a physiologic replacement dosage, and a supraphysiologic dosage. We plan to carefully monitor testosterone levels, side effects, biochemical parameters, and factors related to compliance with therapy. We plan to obtain preliminary information regarding the changes in measurements of muscle strength, total score on an Objective Physical Performance Test, total lean body mass by dual energy x-ray absorptiometry (DEXA), thigh cross-sectional areas by magnetic resonance imaging (MRI), and self-reported performance of activities of daily living, and quality of life. These data will be used to develop a full-scale proposal to test the long-term hypothesis that testosterone therapy combined with exercise training can improve physical function after a hip fracture.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-female, hip fracture repair within previous 4 months

  • age 65 years and older
  • serum total testosterone level < 30 ng/dl
  • modified Physical Performance Test Score between 13-28
  • able to ambulate 50 ft

Exclusion criteria

-permanent nursing home residence

  • dementia severe enough to prohibit informed consent
  • clinically significant visual or hearing impairments
  • history of a hormone dependent neoplasia
  • active or unstable cardiopulmonary disease
  • history of sleep apnea
  • elevated liver function tests
  • hematocrit > 51%
  • history of alcohol or substance abuse
  • symptoms of depression severe enough to cause weight loss of >5% in previous 3 months or interfere with daily activities or medication compliance

Treatment and study plan

Testosterone gel

Drug

Primary outcomes

  1. Serum testosterone levels, drug compliance, symptoms and side effects during the six months of treatment.

    Time frame: Six months

Secondary outcomes

  1. Modified Physical Performance Test Score at 6 months

    Time frame: Six months

  2. 1-RM muscle strength at 6 months

    Time frame: Six months

  3. Thigh cross-sectional area by MRI at 6 months

    Time frame: Six months

  4. Self-report of ADL function at 6 months

    Time frame: Six months

  5. SF-36 score (quality of life) at 6 months

    Time frame: Six months

  6. Total and regional bone density by DEXA at 6 months

    Time frame: Six months

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Collaborators

  • National Institute on Aging (NIA)

Registry information

Important dates

Study start
2004
Primary completion
2006
Study completion
2006
First posted
Jan 20, 2006
Registry last updated
Feb 4, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.